1 Introduction
2 Oncobiosis in breast cancer
Patient cohort Mode of analysis | Changes to the microbiome, biomarker observations, diversity | Reference |
---|---|---|
Changes to the breast tissue microbiome | ||
Breast tissue obtained from surgery of benign tumors (n = 13), cancerous (n = 45), and healthy breast tissue (n = 23) 16S rRNA gene sequencing | The bacterial composition of the healthy breast tissue and breast cancer tissue is different. Higher abundances of Prevotella, Lactococcus, Streptococcus, Corynebacterium, and Micrococcus in healthy breast tissue and Bacillus, Staphylococcus, unclassified Enterobacteriaceae, unclassified Comamonadaceae, and unclassified Bacteroidetes in breast cancer tissue | [55] |
15 malignant cancer (stages I and II) and 13 benign atypia patients 16S rRNA gene sequencing | No significant differences in alpha diversity values, but beta diversity differs between the breast tissue of malignant and benign breast tissue. Fusobacterium, Atopobium, Hydrogenophaga, Gluconacetobacter, and Lactobacillus abundance increased in the tissue of the malignant cases | [56] |
141 breast tissue samples from BC patients | Enterococcus abundance plays a vital role in regional recurrence | [95] |
Changes to the milk duct microbiome | ||
Nipple aspirate fluid from breast cancer surviving patients (n = 6) and healthy controls (n = 9) 16S rRNA gene sequencing | Beta diversity, but not the alpha diversity, is different between breast cancer patients and healthy controls. Alistipes was present only in the nipple aspirate from breast cancer patients, while unclassified Sphingomonadaceae genus was enriched in the nipple aspirate of healthy controls | [57] |
Changes to the breast carcinoma microbiome | ||
Percutan needle biopsy from 22 benign and 72 malignant breast cancer patients 16S rRNA gene sequencing | Slightly higher alpha diversity in patients with malignant disease. Proteobacteria increased in malignant cases. The genus Propionicimonas and the families Micrococcaceae, Caulobacteraceae, Rhodobacteraceae, Nocardioidaceae, and Methylobacteriaceae increased in the malignant disease group | [58] |
8 normal breast tissues, 64 breast tumors, in 11 cases paired non-cancerous adjacent tissue 16S rRNA gene sequencing | Alpha diversity and beta diversity indices were lower in the tumor tissue. Clostridia, Bacteroidia, WPS_2, Ruminococcaceae, Fusobacteria, and Spirochetes increased, while Pseudomonadaceae, Sphingomonadaceae, Caulobacteraceae, Thermi, and Actinobacteria decreased in tumors. Streptococcaceae and Ruminococcus were abundant in TNBC tumors; Xanthomonadales in Luminal A; Clostridium in Luminal B; Akkermansia. Ruminococcaceae and genus Hyphomicrobium were more abundant in stage I Her2 + tumors, Sporosarcina in stage II, Bosea in stage III + IV | [59] |
221 breast cancer specimens, breast tissue from 18 individuals predisposed to breast cancer, and 69 controls 16S rRNA gene sequencing | Alpha diversity values were lower in tumors and the breast tissue of the risk population. Widespread association with stage, lobular or ductal origin, and hormone receptor positivity | [60] |
Cancerous tissue and adjacent healthy tissue from 16 breast cancer patients 16S rRNA gene sequencing | No significant differences in alpha diversity. No difference between the cancerous and the adjacent healthy tissues | [61] |
BC tumor and adjacent normal tissue from 6 + 10 TNBC WNH and 7 TNBC BNH, 7 TPBC WNH, and 3 TPBC BNH 16S rRNA gene sequencing | In triple-positive and triple-negative breast cancer from black non-Hispanic alpha indices decrease, in white non-Hispanic women alpha indices increase Fusobacteria and Streptococcus abundance increase in the tumor. There is a difference between the microbiome composition of triple-positive and triple-negative breast cancers | [63] |
10 archived breast cancer tumor tissue, 10 freshly excised normal breast tissue, 8 of them from both breasts 16S rRNA gene sequencing | Ruminococcaceae, Akkermansia, Verrucomicrobia increased, while Sutterella, Acinetobacter Bacteroides, Cyanobacteria, Proteobacteria, Synergistetes, and Tenericutes decreased in the tumor tissue. Alpha index decreased in the tumor tissue | [62] |
44 BC patients and 20 controls. Significant age and body mass index difference between cohorts 16S rRNA gene sequencing | No significant difference in alpha diversity. Methylobacterium decreased in cancer patients and was drastically reduced when invasion was reported. In cancer patients, levels of gram-positive organisms including Corynebacterium, Staphylococcus, Actinomyces, and Propionibacteriaceae increased | [54] |
100 TNBC, 17 matched, 20 non-matched controls PathoChip technology | Higher association of Brevundimonas diminuta, Arcanobacterium haemolyticum, Peptoniphilus indolicus, Prevotella nigrescens, Propiniobacterium jensenii, and Capnocytophaga canimorsus and a set of viruses and fungi are associated with TNBC samples compared to normal tissues | [64] |
50 BRER, 34 BRHR, 24 BRTP, 40 TNBC, 20 controls PathoChip technology | BRER is characterized by Arcanobacterium, Bifidobacterium, Cardiobacterium, Citrobacter, and Escherichia species; BRTP is characterized by Bordetella, Campylobacter, Chlamydia, Chlamydophila, Legionella, and Pasteurella; BRHR is characterized by Streptococcus; TNBC is characterized by Arcobacter, Geobacillus, Orientia, and Rothia | [65] |
Healthy (age-matched) (n = 23), paired normal (n = 39), and tumor tissue (n = 39) 16S rRNA gene sequencing | Bacterial copy number decreased in tumors and with increased grade. Sphinomonadaceae family, Sphingomonas species decreased, while the Methylobacteriaceae family, Methylobacterium species increased in tumors | [66] |
668 breast tumor and 72 non-cancerous breast tumor sequences from the TCGA data portal | Salmonella enterica, Escherichia coli, Bacillus alcalophilus, Brachybacterium muris, Plesonius fermentans, Mycobacterium phlei, and Acinetobacter radioresistens increased, while Microbacterium barkeri, Acinetobacterium baumannii, Ralstonia pickettii, Lactobacillus rossiae, and Mycobacterium fortuitum decreased in the tumors | [68] |
256 normal tissue and 355 breast tumors | Bacterial LPS and 16S RNA were detected in breast cancer cells in breast tumors. The microbiome of the breast tumors was richer than other tumors assessed and in normal adjacent breast tissue. Proteobacteria, Firmicutes, and Actinobacteria can be found in breast tumors. Differences in ER + and ER- breast tumors | [67] |
21 female and 2 male BC patients 16S rRNA gene sequencing | Compared to normal breast tissue, the abundance of Proteobacteria increased in tumor tissue | [69] |
95–105 FFPE samples for each BC subtype, 86 controls Pathochip | Large set of viruses, parasites, and fungi were detected in FFPE sections of breast cancer. The least of these were detected in TNBC cases | [70] |
16 healthy controls, 32 breast cancer patients 16S rRNA gene sequencing | The abundance of Corynebacterium, Prevotella, and Gammaproteobacteria (unclassified) decreased, while Acinetobacter increased in BC tissue | [71] |
Changes to the gut microbiome | ||
48 postmenopausal BC patients (most stages 0–I), vs. 48 control patients 16S rRNA gene sequencing | Breast cancer patients had a higher abundance of Clostridium, Faecalibacterium, and Ruminococcus (all Clostridiales) and a lower abundance of Dorea and Lachnospiraceae Lower number of observed species, Chao1 and PD whole tree indices in breast cancer patients | [73] |
30 BC and 36 control patients Classical bacterial culture | Fecal bile acid levels were lower in breast cancer patients. Bacterial nuclear dehydrogenating activity increased in breast cancer patients suggesting increases in Clostridia abundance in feces | [82] |
18 premenopausal BC patients, 25 premenopausal controls, 44 postmenopausal BC patients, 46 postmenopausal healthy controls Comprehensive shotgun sequencing | Species number, chao1, and JSD values were higher in postmenopausal cancer patients than in controls. Widespread taxonomical changes in BC patients | [75] |
379 BC patients, 102 non-malignant breast disease, 414 population-based controls 16S rRNA gene sequencing | Alpha diversity indices correlate negatively with the odds for BC, BC grade, and subtype. No difference in the microbiome of malignant and non-malignant patients, but differ when compared to controls. Bacteroides, Flavonifractor, and Ruminococcaceae strongly and positively associated with BC, while Rombutsia, Coprococcus 2, Christensenellaceae R-7 group, Dorea, [Eubacterium] coprostanoligenes group, Pseudobutyrivibrio, and Lachnospira negatively associated with BC | [74] |
32 overweight stage 0–II BC patients 16S rRNA gene sequencing | Akkermansia high abundance patients had higher alpha diversity compared to low abundance patients | [52] |
31 female BC patients 16S rRNA gene sequencing | Total bacterial count decreased in overweight patients. The abundance of Firmicutes, Faecalibacterium prausnitzii, Blautia sp., and Eggerthella lenta decreased in overweight patients. Blautia sp. abundance increased as a function of tumor grade. Bacteroidetes, Clostridium coccoides, Clostridium leptum, Faecalibacterium prausnitzii, and Blautia sp. increased in stage II–III patients compared to stage 0–I patients | [77] |
37 incident BC patients 16S rRNA gene sequencing | Early menarche patients had lower Chao1 and OTU indices and lower Firmicutes abundance. Lower OTU, Chao1, and Shannon indices; lower Blautia, Coprococcus, Ruminococcus, and Oscillospira; and higher Firmicutes abundance in Her2 − cases compared to Her2 + cases. Clostridium and Vellionella increased in grade III patients. High total body fat was associated with lower Chao1 and OTU indices | [51] |
48 postmenopausal BC case patients (most stages 0–I), vs 48 control patients (same as [73]) qPCR of specific loci | Abundance of DNA coding for the baiH gene of Clostridium sordelli, Bacteroides thetaiotaomicron, Escherichia coli, Pseudomonas putida, and Staphylococcus haemolyticus decreased in breast cancer patients, the most pronounced changes were detected in in situ carcinoma patients | [78] |
48 postmenopausal BC case patients (most stages 0–I), vs 48 control patients (same as [73]) qPCR of specific loci | Abundance of DNA coding for the CadA gene of Escherichia coli and the LdcC gene of Escherichia coli, Enterobacter cloacae, and Hafnia alvei decreased in breast cancer patients, the most pronounced changes were detected in in situ carcinoma patients | [79] |
3 control and 4 stage I BC patients Western blotting | Fecal expression of Escherichia coli LdcC protein was lower in stage I patients | |
48 postmenopausal BC case patients (most stages 0–I), vs 48 control patients (same as [73]) qPCR of specific loci | Abundance of DNA coding for the TnaA gene of Alistipes shahii, Providencia rettegri, Bacteroides xylanisolvens, and Clostridium sp. decreased in breast cancer patients, the most pronounced changes were detected in in situ carcinoma patients | [80] |
35 BC patients Western blotting | Fecal expression of Escherichia coli TnaA was higher in patients with tumor-infiltrating lymphocyte (TIL) ratio over 20% compared to that of those below. Fecal E. coli TnaA expression correlated with TIL percentage | |
35 BC cases Western blotting | Fecal expression of TnaA Escherichia coli LdcC protein was lower in lobular cases | [81] |
48 postmenopausal BC cases, 48 control 16S rRNA gene sequencing | Lower alpha diversity in breast cancer patients. Lower alpha diversity among IgA-coated bacteria | [83] |
124 BC survivor patients 16S rRNA gene sequencing | Abundance of Actinobacteria (Bifidobacterium) was associated with increased levels of DHA. Abundance of Bacteroidetes negatively correlated with EPA levels that were abrogated in patients receiving chemotherapy | [85] |
30 controls vs. 25 BC cases 16S rRNA gene sequencing | In breast cancer patients, Bacteroidetes phylum, Clostridium cluster IV, Clostridium cluster XIVa, and Blautia sp. decreased, and Firmicutes phylum increased. No difference in the total number of bacteria. Alpha diversity increased in patients | [84] |
200 BC patients (stages I–II) and 67 controls 16S rRNA gene sequencing | Alpha diversity lower in premenopausal patients, no difference in the postmenopausal cohort; beta diversity is different. Bacteroidetes proportions increased in BC patients | [87] |
76 BC patients (35 stage II/III, 21 stage I), 336 healthy volunteers Comprehensive shotgun sequencing | 52 units, mostly at the species level, decreased, while 38 units increased in breast cancer patients compared to healthy volunteers. 11 species increased in stage II/III patients, while 21 species increased in stage I patients | [86] |
83 invasive BC patients, 19 patients with benign breast tumors 16S rRNA gene sequencing | No difference in alpha and beta diversity indices. The abundance of Clostridium, Faecalibacterium, Lachnospira, Erysipelotrichaceae, Romboutsia, Fusicatenibacter, Xylophilus, and Arcanobacterium decreased, while the abundance of Citrobacter increased in malignant BC patients. Distinct patterns identified BC subtypes and a microbial pattern associated with highly proliferative tumors | [89] |
Changes to the urinary microbiome | ||
44 BC patients and 20 controls. Significant age and body mass index difference between cohorts 16S rRNA gene sequencing | Cancer patients had significantly higher Shannon index. Peri/postmenopausal urinary microbiome had higher Shannon index compared to premenopausal samples. Corynebacterium, Staphylococcus, Actinomyces, and Propionibacteriaceae abundance increased in cancer patients | [54] |
220 controls and 127 BC patients 16S rRNA gene sequencing of the bacterial extracellular vesicles | The abundance of Bacteroides and Ruminococcaceae-derived extracellular vesicles were higher in the breast cancer group, while Clostridiales and Pseudomonas-derived extracellular vesicles were more abundant in healthy controls | [90] |
3 Interactions between the oncobiome, tumors, and tumor cells
3.1 Tumor colonization
Bacterial pathway | Study |
---|---|
Stage I tumors were enriched in energy metabolism, fat digestion, and absorption | [59] |
Stage II tumors are enriched in phosphotransferase system proteins | |
Increased in benign cases: | [56] |
Cysteine metabolism | |
Methionine metabolism | |
Glycosyltransferases | |
Fatty acid biosynthesis | |
Branched dibasic acid metabolism | |
Increased in malignant cases: | |
Drug metabolism (other enzymes) | |
Inositol phosphate metabolism | |
Upregulated in breast cancer cases: | [67] |
Dermatan sulfate degradation | |
Indole acetate biosynthesis | |
L-ascorbate biosynthesis II (L-glucose pathway) | |
Mycothiol biosynthesis | |
Upregulated in breast cancer cases: | [55] |
Colibactin biosynthesis | |
Upregulated in breast cancer cases: | [57] |
Flavone and flavonol biosynthesis (incl. beta-glucuronidase) | |
Isoflavonoid biosynthesis | |
Flavonoid biosynthesis | |
Steroid hormone biosynthesis | |
Synthesis and degradation of ketone bodies | |
Tryptophan metabolism | |
Sulfur metabolism | |
Lipopolysaccharide biosynthesis | |
Sphingolipid metabolism | |
Polycyclic aromatic hydrocarbon degradation | |
Glycine, serine, and threonine biosynthesis | |
Oxidative phosphorylation | |
Benzoate degradation | |
Phenylalanine biosynthesis | |
Peptidoglycan biosynthesis | |
Linoleic acid biosynthesis | |
Nitrogen metabolism | |
Upregulated in breast cancer cases: | [62] |
Base excision repair | |
Th17 cell differentiation | |
Choline metabolism | |
Central carbon metabolism | |
Necroptosis, microRNAs involved in carcinogenesis | |
Proteoglycans involved in carcinogenesis | |
Signaling pathways including IL-17, PI3K-Akt, HIF-1, and AMPK |
3.2 Bacterial metabolite signaling and the oncobiosis of the gastrointestinal tract and urinary tract
Metabolite group | Made from | Producing bacteria | Relevant enzyme(s) | Receptor | Effect | ||||
---|---|---|---|---|---|---|---|---|---|
Ref | Ref | Ref | Ref | ||||||
Reactivated estrogens | Conjugated estrogens | Firmicutes Collinsella Edwardsiella Alistipes Bacteroides Bifidobacterium Citrobacter Clostridium Dermabacter Escherichia Faecalibacterium Lactobacillus Marvinbryantia Propionibacterium Roseburia Tannerella | β-glucuronidase (gus/BC) | ERα ERβ mER (mERα, mERβ, GPER, GPRC6, ER-X, Gq-mER) | OXPHOS, tamoxifen resistance, metastasis, aggressivity, hormone-induced apoptosis, EMT, proliferation, metastasis | ||||
Short-chain fatty acids Acetate Butyrate Formate Lactate Propionate Pyruvate | Non-digestible carbohydrates, branched Chain amino acids | Akkermansia muciniphila Lachnospiraceae Ruminococcus obeum Roseburia inulinivorans Bacteroidetes Negativicutes sp. Faecalibacterium Prausnitzii Eubacterium rectale Roseburia faecis Eubacterium hallii SS2/1 Odoribacter Anaeotruncus | Thioesterases, phosphate acetyltransferase, acetate kinase, phosphate butyryltransferase, butyrate kinase, lactate dehydrogenase | [150] | FFAR HDAC AHR | OXPHOS (direct energy substrates), apoptosis, HDAC inhibition, macrophage antimicrobial activity | |||
Secondary bile acids LCA DCA UDCA | CDCA CA 7-keto-litocholic acid | Clostridium Enterococcus Bifidobacterium Lactobacillus Streptococcus Eubacterium Listeria Bacteroides Methanobrevibacter Methanosphera Escherichia Ruminococcus | Bile salt hydrolases (BSH), 7α/β -hydroxysteroid, dehydroxylase (baiH) | [167] | TGR5 FXR SHP | Apoptosis, proliferation, VEGF production, OXPHOS, antitumor immunity, EMT, fatty acid biosynthesis, movement, metastasis formation, increased oxidative and nitrosative stress | |||
Biologically active amines Cadaverine | L-lysine | Shigella flexneri Shigella sonnei Escherichia coli Streptococci | Lysine decarboxylase (LdcC, CadA) | TAAR1, 2, 3, 5, 8, 9 | [174] | OXPHOS, CSC, movement, invasion, EMT, metastasis formation | [79] | ||
Indole derivatives Indoxyl sulfate Indolepropionic acid | Tryptophan | Providencia rettgeri Alistipes shahii Bacteroides xylanisolvens Clostridium Lactobacillus reuteri | TnaA SULT1, Cyp2e1 | [176] [176] | AHR PXR | [176] | OXPHOS, CSC, movement and proliferation, invasion, EMT, metastasis formation, antitumor immunity |
Metabolite group | Made from | Producing bacteria | Relevant enzyme(s) | Receptor | Effect | ||||
---|---|---|---|---|---|---|---|---|---|
Ref | Ref | Ref | Ref | ||||||
LPS | Lipid A + core oligosaccharide + O-specific polysaccharide | Escherichia coli Salmonella enterica Vibrio cholera Pseudomonas Pantoea | [177] | Lpx | TLR2 TLR4 | Apoptosis, migration and metastases, EMT and β-catenin signaling, invasiveness | |||
Lysophospholipids (LPS) Lysophosphatidic acid (LPA) | Phospholipid | Vibrio cholerae Helicobacter pylori Yersinia pseudotuberculosis | [184] | Phospholipase A2 Exogenous lipase | [184] | LPAR1-5 | Proliferation, migration, metastasis, stress fiber and focal adhesion formation | ||
Colibactin | Precolibactin | Escherichia coli Klebsiella pneumoniae Enterobacter aerogenes Citrobacter koseri | [190] | ClbA-S | [190] | Unknown | Unknown |
Induced in BC patients | Decreased in BC patients | Ref |
---|---|---|
Premenopausal patients Beta oxidation Pyridoxal biosynthesis Pentose phosphate pathway (oxidative) Heparane sulfate degradation Entner-Duodoroff pathway | Premenopausal patients Uridine monophosphate biosynthesis Reductive pentose phosphate cycle (ribulose5P → glyceraldehyde3P) Pyruvate oxidation to acetyl-CoA Phosphatidylethanolamie biosynthesis Inosine monophosphate biosynthesis Glycolysis GABA biosynthesis Formaldehyde assimilation, serine pathway F-type ATPase Dicarboxylate pathway Pantothenate biosynthesis C5 isopernoid biosynthesis, non-mevalonate pathway C1-unit interconversion | [75] |
Postmenopausal patients Ubiquinone biosynthesis Jasmonic acid biosynthesis Beta oxidation LPS biosynthesis Glyoxylate cycle | [75] | |
Meta cleavage pathway of aromatic compounds Aromatic biogenic amine degradation Androstenedione degradation | [87] | |
LPS biosynthesis Ubiquinone and other terpenoid-quinone biosynthesis Folate biosynthesis Aminobenzoate degradation Biotin metabolism Glutathione metabolism Penicillin and cephalosporin biosynthesis D-Arginine and D-ornithine metabolism N-glycan biosynthesis Isoquinoline alkaloid biosynthesis Styrene degradation TCA cycle Geraniol degradation Indole alkaloid biosynthesis | Glycolysis/gluconeogenesis Glycerophospholipid metabolism | [89] |